Fig. 3From: Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degenerationNumber of eyes with either subretinal fluid (SRF) or intraretinal fluid (IRF), SRF only, or IRF only on optical coherence tomography at baseline and following 12 months of intravitreal aflibercept treatmentBack to article page